Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Seaport Therapeutics to Present at Stifel 2025 Healthcare Conference

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference

Tango Therapeutics Announces $225 Million Financing

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer

Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform 

Synnovation to Present SNV1521 (PARP1) Phase 1 Study Results at the European Medical Oncology (ESMO) Congress 2025 and Announces Clinical Collaboration with DualityBio to Evaluate the Combination of SNV1521 with Duality’s HER3 ADC, DB-1310

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Fierce Biotech Names Trace Neuroscience a “Fierce 15” Biotech Company of 2025

Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree

Seaport Therapeutics to Participate in Upcoming Investor Conferences

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo (SPT-320) in Healthy Volunteers

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001

insitro partners with Lilly to build first-in-kind machine learning models to advance small molecule drug discovery

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizuresra

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseasesse

Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer

Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure

MOMA Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial for MOMA-341,a Highly Potent and Selective Werner Helicase Inhibitor

Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress

Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025

Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025

Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation

Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease

Septerna to Present at Jefferies Global Healthcare Conference

Flare Therapeutics to Participate in Jefferies Global Healthcare Conference